LeaderMed Group and Combiphar Form Joint Venture on LM-008, a Novel GLP-1 Dual Agonist, Targeting Indonesia's High Diabetes and/or Obesity Prevalence LeaderMed and Combiphar form a joint venture to tackle Indonesia’s diabetes and obesity crisis with LM-008 and UltraSculpt, launching a Phase 3 trial.